NBP — NovaBridge Biosciences Income Statement
0.000.00%
Last trade - 00:00- $326.33m
- $160.71m
- 68
- 64
- 75
- 79
Annual income statement for NovaBridge Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 224 | 13.6 | -1.55 | 0.632 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | 6.45 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 142 | 335 | 51.5 | 72.6 | 65.1 |
| Operating Profit | 81.6 | -321 | -53.1 | -72 | -65.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 70 | -362 | -141 | -82.2 | -49.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 68.3 | -361 | -141 | -82.2 | -49.7 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 68.3 | -361 | -371 | -208 | -22.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 68.3 | -361 | -371 | -208 | -22.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.068 | -2.07 | -0.744 | -0.309 | -0.193 |